More recently, systemic inflammation based prognostic scores such as the modified Glasgow Prognostic Score (mGPS, a combination of C-reactive protein and albumin), have been developed [7] and found to have significant prognostic value in one-year and five-year survival from prostate cancer [11]. This evidence concerns the gene ALB and Familial prostate cancer.